Ipamorelin the science.

Ipamorelin is a synthetic five-amino-acid peptide in the growth-hormone-releasing-peptide family. Its defining feature in the research literature is selectivity: it activates the growth-hormone-secretagogue receptor (GHS-R1a) to evoke GH release while, in preclinical studies, producing minimal release of cortisol, prolactin, or other pituitary hormones — a contrast with earlier, less selective GHRPs.

This selectivity is the central research interest, making ipamorelin a useful tool for isolating GHS-receptor-driven GH release from confounding hormonal effects. It is an investigational compound, not an approved medicine.

Ipamorelin research is organized around selective GHS-receptor activation:

• GHS-R1a activation — binding the ghrelin receptor on pituitary somatotrophs is studied for how it triggers GH secretion.
• Hormonal selectivity — investigators examine why ipamorelin evokes GH release with minimal cortisol or prolactin response in preclinical models.
• GHRH synergy — combined GHS- and GHRH-receptor activation is studied for an amplified GH response.

Ipamorelin literature is largely preclinical, concentrated in rodent and cell models:

• Selectivity characterization (1998). A study in the European Journal of Endocrinology described ipamorelin as the first selective GH secretagogue, reporting potent GH release with minimal effect on other pituitary hormones in animal models.
• Receptor & tissue models. Subsequent preclinical work examined GHS-receptor binding and effects in tissue models such as bone.

These are findings in animals and cells. Dedicated human clinical evidence for ipamorelin is limited.

The ipamorelin evidence base is predominantly preclinical, characterized chiefly in animal and cell models; dedicated human clinical-trial data is limited. No human safety, dosing, or efficacy is established here. Ipamorelin is supplied strictly as a research material for laboratory investigation.